60
Participants
Start Date
January 1, 2021
Primary Completion Date
June 1, 2025
Study Completion Date
June 1, 2025
Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet
Subjects will receive a single dose of carbidopa/levodopa, when applicable.This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
Naproxen 500 Mg
Subjects will receive a single dose of naproxen 500mg alongside carbidopa/levodopa, when applicable.This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
Opioids
Subjects will be pre-screened in regards to their opioid medication. They will receive a single dose of their opioid dose, when appropriate. This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
Northwestern University Feinberg School of Medicine, Chicago
Shirley Ryan AbilityLab
OTHER
National Institutes of Health (NIH)
NIH
Northwestern University
OTHER